Annexin A2 and CD105 Expression in Pancreatic Adenocarcinoma Associated with Tumor Recurrence and Prognosis

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with an actuarial mortality rate is about 90% (Cheung, 2013), corresponding to the fourth leading cause of cancer death. Worldwide, the incidence of all types of pancreatic cancer (85% of which are PDAC) ranges from 1 to 10 cases per 100, 000 people (Ryan et al., 2014), Accounted for 2% of all malignant tumor incidence in china. At present, The 5-year survival rate of PDAC was only 3-5%, was the lowest in all cancers. Annexin A2 (ANXA2) also known as LPC2, LIP2, P36, was a member of annexin family. Annexin A2 has been considered to participate in a range of physiological processes, including anti-inflammatory, anti-coagulation, , exocytosis, endocytosis and signal transduction, cellproliferation, diffrentiation, and apoptosis (Gurluler et al., 2014). The disorder of Annexin A2 expression is related to the tumorigenesis in a variety of tumor, The data shows Annexin A2 play an important role in the process of tumor invasion and metastasis, and could be used as predictor biomarker of cancer (Alonso-Alconada et al., 2014). Microvessel density (MVD) is the most recognized indicator to evaluate angiogenesis of solid tumors, CD105 (endoglin) was a high affinity coreceptor for transforming growth factor (TGF)-β1 and TGF-β3 (Anderson et al., 2013), and was overexpressed in the tumor-associated vascular endothelium where it modulates